Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p after the company announced it would discontinue its United States Food and Drug Administration establishment licence and device listing for its Parsortix system.
The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support cancer research and drug development, said the decision reflected its revised business model and customer usage patterns.
More than 97% of Parsortix platforms in the field are deployed for in-house translational research and assay development activities, where an active device listing provides no commercial benefit.
Streamlining these expenses will allow the AIM-listed company to reallocate resources to areas that directly support revenue growth, customer support and product development.
CelLBxHealth said it retains the flexibility to reinstate the device listing at any time through payment of the applicable annual fees should commercial opportunities make it advantageous to do so.
The change has no impact on the company's sales pipeline, market forecasts, customer support or ongoing partnerships.
Peter Collins, chief executive, said the decision was "a practical step that reflects how our customers are using the Parsortix platform today".